Ron Moldaver | Investor Relations |
Jim Mullen | Executive Chairman |
Gilmore O’Neill | Chief Executive Officer |
Mark Shearman | Chief Scientific Officer |
Michelle Robertson | Chief Financial Officer |
Baisong Mei | Chief Medical Officer |
Gena Wang | Barclays |
Joon Lee | Truist Securities |
Dae Gon Ha | Stifel |
Jay Olson | Oppenheimer |
Luca Issi | RBC Capital Markets |
Rick Bienkowski | SVB Securities |
Philip Nadeau | Cowen and Company |
Joel Beatty | Robert W. Baird |
Yanan Zhu | Wells Fargo Securities |
Ryan Deschner | Raymond James |
Good morning and welcome to Editas Medicine’s Second Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company’s request. I would now like to turn the call over to Ron Moldaver, Investor Relations at Editas Medicine.